Known targets — ChEMBL curated mechanism
DHFRGARTPTGFRPTGIRPTGS1PTGS2TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8envmurAthyA
The experimentally established mechanism targets of Lodoxamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 13/20 | 0.76 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.34 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.34 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.34 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | PTPRA | P18433 | 1/20 | 0.33 |
| ▸ | TRPM4 | Q8TD43 | 1/20 | 0.32 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tromethamine SCHEMBL18190767 | 0.92 | GPR35 (0.64) | GPR35PDK1PDK2PDK3PDK4 | |
| Lodoxamide SCHEMBL11864397 | 0.88 | GPR35 (0.78) | GPR35PDK1PDK2PDK3PDK4 | |
| Lodoxamide SCHEMBL119881 | 0.87 | GPR35 (1.00) | GPR35PTPN1PTPRAPIN1 | |
| Lodoxamide SCHEMBL3141058 | 0.85 | GPR35 (0.97) | GPR35PTPN1PTPRAPIN1 | |
| Lodoxamide SCHEMBL10897004 | 0.84 | GPR35 (0.88) | GPR35PTPN1PTPRAPIN1 | |
| SCHEMBL11946654 | 0.83 | GPR35 (0.90) | GPR35PTPN1PTPRAPIN1 | |
| SCHEMBL28582660 | 0.80 | GPR35 (0.79) | GPR35MEN1KMT2APIN1 | |
| SCHEMBL11703780 | 0.79 | GPR35 (0.63) | GPR35PDK1PDK2PDK3PDK4 | |
| SCHEMBL12803235 | 0.78 | GPR35 (0.80) | GPR35PDK1PDK2PDK3PDK4 | |
| SCHEMBL6439833 | 0.73 | GPR35 (0.63) | GPR35MEN1KMT2ATRPM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1239 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| EP-4590283-A1 | MUCOADHESIVE DRUG DELIVERY SYSTEMS AND METHODS OF USE | Madd Ophthalmics Ltd. (CA) | 2025-07-30 | — | — | EP | claimed |
| US-12274681-B2 | Compositions and methods for reducing skin fat | PURDUE RESEARCH FOUNDATION (US) | 2025-04-15 | — | — | US | claimed |
| WO-2024258363-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | SAHIN FIKRET (TR) | 2024-12-19 | — | — | WO | claimed |
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| WO-2024059952-A1 | MUCOADHESIVE DRUG DELIVERY SYSTEMS AND METHODS OF USE | MADD OPHTHALMICS LTD. (CA) | 2024-03-28 | — | — | WO | claimed |
| US-20230285286-A1 | DRUG VEHICLE COMPOSITIONS AND METHODS OF USE THEREOF | PS THERAPY INC (US) | 2023-09-14 | — | — | US | claimed |
| US-20230270701-A1 | COMPOSITIONS AND METHODS FOR REDUCING SKIN FAT | PURDUE RESEARCH FOUNDATION | 2023-08-31 | — | — | US | claimed |
| CN-112961076-B | Preparation method of lodoxylamine tromethamine impurity | 武汉先路医药科技股份有限公司 | 2023-04-14 | — | — | CN | claimed |
| US-20230102547-A1 | ANTERIOR SEGMENT DRUG DELIVERY | FORSIGHT VISION5, INC. | 2023-03-30 | — | — | US | claimed |
| WO-2007106381-A2 | OPHTHALMIC COMPOSITIONS COMPRISING POVIDONE-IODINE | CLS PHARMACEUTICALS, INC. (US) | 2007-09-20 | — | — | WO | claimed |
| US-20060263350-A1 | Combination antihistamine medication | FAIRFIELD CLINICAL TRIALS LLC (US) | 2006-11-23 | — | — | US | claimed |
| US-20060228306-A1 | Combination antihistamine and steroid medication | FAIRFIELD CLINICAL TRIALS LLC (US) | 2006-10-12 | — | — | US | claimed |
| WO-2006051287-A1 | COMPOSITION AND METHOD FOR TREATMENT OF ALOPECIA AREATA | ARROW INTERNATIONAL LIMITED (MT) | 2006-05-18 | — | — | WO | claimed |
| WO-2005030331-A1 | COMBINATION ANTIHISTAMINE MEDICATION | FAIRFIELD CLINICAL TRIALS, LLC (US) | 2005-04-07 | — | — | WO | claimed |
| CN-1483478-A | Eye preparation formula adapted for therapentic medicine | 无锡杰西医药科技有限公司 | 2004-03-24 | — | — | CN | claimed |
| US-20010049369-A1 | Brimonidine compositions and methods for retinal degeneration | UNIVERSITY OF TENNESSEE RESEARCH CORPORATION, THE | 2001-12-06 | — | — | US | claimed |
| US-5457126-A | Applying optically to affected eye a mixture of antiallergens | ALCON LABORATORIES, INC. (US) | 1995-10-10 | — | — | US | claimed |
| EP-0433766-A1 | Compositions of antiallergics and antihistamines and methods for their use | ALCON LABORATORIES, INC. (US) | 1991-06-26 | — | — | EP | claimed |
| US-4524063-A | TOPICAL LODOXAMIDE TROMETH AMINE AQUEOUS SOLUTION CONTAINING POLYVINYL ALCOHOL; ANTIALLERGENS | ALLERGAN PHARMACEUTICALS, INC. (US) | 1985-06-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010049369-A1 | Brimonidine compositions and methods for retinal degeneration | NR2E3, MTNR1A, MTNR1B | GPR35 502/4885PDK1 2446/4885PDK2 2121/4885 |
| US-12274681-B2 | Compositions and methods for reducing skin fat | ACAT1, ACAT2, ACACA | GPR35 2771/4885PDK1 1379/4885PDK2 1121/4885 |
| US-20230270701-A1 | COMPOSITIONS AND METHODS FOR REDUCING SKIN FAT | ACAT1, ACAT2, ACACA | GPR35 2771/4885PDK1 1379/4885PDK2 1121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.